IMUX
Immunic, Inc.
There isn't enough reported data to score IMUX yet.
IMUX Fundamentals
| Metric | Status |
|---|---|
| Unavailable | |
| Under pressure | |
| Unavailable | |
| Unavailable |
IMUX's profitability is currently under pressure. There isn't enough data to rate its revenue, cash flow and balance sheet.
IMUX PE Valuation
IMUX has no meaningful PE right now: it lost money over the past year.
IMUX Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses shrinking | |
| -- | |
| -- | |
| Limited | |
| Low |
Analysts expect IMUX's losses to shrink, with revenue holding steady. However, they disagree widely on these estimates.
IMUX Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q2 2026 | -$3.58 | +$5.82 |
| Q1 2026 | -$4.78 | +$4.72 |
| Q4 2025 | -$6.20 | +$3.80 |
| Q3 2025 | -$8.30 | +$4.00 |
| Q2 2025 | -$9.40 | +$5.60 |
| Q1 2025 | -$9.50 | +$8.80 |
| Q4 2024 | -$10.00 | +$11.10 |
| Q3 2024 | -$12.30 | +$20.30 |
IMUX is still losing money, but far less than before: $3.58 per share over the past year, against $135.40 at its worst in late 2019.
IMUX Quarterly Revenue
IMUX Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q2 2026 | -$31.2M | -$6.6M |
| Q1 2026 | -$17.3M | +$4.5M |
| Q4 2025 | -$19.3M | +$3.7M |
| Q3 2025 | -$20.2M | +$646K |
| Q2 2025 | -$24.6M | -$7.4M |
| Q1 2025 | -$21.8M | +$2.2M |
| Q4 2024 | -$23M | -$8.8M |
| Q3 2024 | -$20.9M | -$3.5M |
IMUX has burned cash in almost every quarter: −$88M over the past year, against −$90M the year before.
IMUX Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +41% | +12.4M shares |
| 1 year | +222% | +29.3M shares |
| 3 years | +874% | +38.1M shares |
| 5 years | +2210% | +40.7M shares |
IMUX has 43M diluted shares, up 222% from a year ago.
IMUX Net Leverage
IMUX's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
IMUX Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 36.9 | Neutral |
| Stochastic | 12.0 | Oversold |
IMUX's weekly RSI is 37 (neutral) and its Stochastic is 12 (oversold).
IMUX PE vs Healthcare Sector
IMUX has no meaningful PE right now: it lost money over the past year.
IMUX Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $7.87 | 1% below |
| 20 week MA | $11.6 | 33% below |
| 50 week MA | $10.6 | 26% below |
| 100 week MA | $9.94 | 22% below |
| 200 week MA | $12.4 | 37% below |
IMUX is in a downtrend: it's below all five of its weekly moving averages, and 37% below its 200-week average.
IMUX Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $92.7 | $169.7 | +83% |
| 2021 | $169.7 | $99.0 | -42% |
| 2022 | $99.0 | $13.0 | -87% |
| 2023 | $13.0 | $15.0 | +15% |
| 2024 | $15.0 | $10.3 | -31% |
| 2025 | $10.3 | $5.61 | -46% |
| 2026 YTD | $5.61 | $7.79 | +39% |
IMUX is up 39% so far in 2026, after finishing lower in four of the previous six years.